{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:22Z","timestamp":1793109742581,"version":"4.5.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"\n Importance<\/jats:title>\n Drug survival is an important measure to help guide treatment selection. However, clinical evidence for newer biologics, including bimekizumab, is limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the drug survival of biologics used for treating psoriasis in a routine clinical practice setting.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study was based on data from the DERMBIO registry, which includes all patients treated with biologics for psoriasis in Denmark. All adult patients enrolled in DERMBIO from its inception in May 2007 until June 2025 were assessed for eligibility. Data were extracted in June 2025 and analyzed separately among those without previous biologic exposure (bionaive patients) and those with previous biologic exposure (bioexperienced patients).<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Adalimumab, secukinumab, and ustekinumab among bionaive patients and adalimumab, bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab among bioexperienced patients.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was standardized absolute risks of treatment discontinuation at 1, 2, and 5 years. Kaplan-Meier estimator was used to determine crude drug survival estimates and the Aalen-Johansen estimator was used to determine crude cause-specific absolute risks.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study included 4438 unique patients with psoriasis (2717 [61.2%] male; mean [SD] age, 45.0 [14.6] years at the time of their first treatment included in the study), 1039 (23.4%) of whom had comorbid psoriatic arthritis. A total of 3790 treatment series from bionaive patients were analyzed: 2646 were with adalimumab, 377 with secukinumab, and 767 with ustekinumab. The 5-year standardized risk of discontinuing ustekinumab was 0.37 (95% CI, 0.33-0.41), which was significantly lower than the standardized risks for adalimumab (0.51; 95% CI, 0.49-0.54) and secukinumab (0.54; 95% CI, 0.48-0.60). A total of 3403 treatment series from bioexperienced patients were analyzed: 790 were with adalimumab, 376 with bimekizumab, 192 with brodalumab, 218 with guselkumab, 556 with ixekizumab, 78 with risankizumab, 466 with secukinumab, and 727 with ustekinumab. The 2-year standardized absolute risk of discontinuing ustekinumab was 0.39 (95% CI, 0.36-0.43). Only bimekizumab (0.27; 95% CI, 0.20-0.34), guselkumab (0.29; 95% CI, 0.22-0.36), and risankizumab (0.25; 95% CI, 0.15-0.36) were associated with a significantly lower standardized absolute risk of discontinuation compared with ustekinumab.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.5205","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:31:10Z","timestamp":1767803470000},"page":"166","source":"Crossref","is-referenced-by-count":6,"title":["Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis"],"prefix":"10.1001","volume":"162","author":[{"given":"Christopher Willy","family":"Schwarz","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital\u2013Herlev and Gentofte, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital\u2013Herlev and Gentofte, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Erik","family":"Bryld","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital, Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer Valdemar","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Dermatology, Copenhagen University Hospital\u2013Bispebjerg, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawa Khaled","family":"Ajgeiy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Bertelsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper Fjellhaugen","family":"Hjuler","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas Norman","family":"Dam","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Nykoebing Falster, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Kirchheiner","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital\u2013Herlev and Gentofte, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"doi250064r1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub6","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"doi250064r2","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis.","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"6","key":"doi250064r3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","article-title":"Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study.","volume":"23","author":"Torres","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"doi250064r4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3?years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.","volume":"188","author":"Strober","year":"2023","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi250064r5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR.","volume":"154","author":"Mason","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi250064r6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/24755303241234292","article-title":"Characteristics of patients with psoriasis treated with various biologics - a Danish cohort study.","volume":"9","author":"Schwarz","year":"2024","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"6","key":"doi250064r7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis.","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"9596","key":"doi250064r8","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"2","key":"doi250064r9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"key":"doi250064r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - a nationwide cohort study from the DANBIO and DERMBIO registries.","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"doi250064r11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/ije\/dyr213","article-title":"Competing risks in epidemiology: possibilities and pitfalls.","volume":"41","author":"Andersen","year":"2012","journal-title":"Int J Epidemiol"},{"issue":"3","key":"doi250064r12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"mice: multivariate imputation by chained equations in R.","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"doi250064r13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/CLEP.S129785","article-title":"Missing data and multiple imputation in clinical epidemiological research.","volume":"9","author":"Pedersen","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"6","key":"doi250064r14","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1080\/09546634.2022.2082354","article-title":"Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.","volume":"33","author":"Kojanova","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi250064r15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ddg.15251","article-title":"Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.","volume":"22","author":"Mastorino","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10","key":"doi250064r16","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/jdv.20739","article-title":"Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists Biologics and Immunomodulators Register cohort study.","volume":"39","author":"Motedayen Aval","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi250064r17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2024.05.085","article-title":"Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 52-week multicenter retrospective study.","volume":"91","author":"Sood","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250064r18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jaad.2025.04.038","article-title":"Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.","volume":"93","author":"Blauvelt","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250064r19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis.","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"doi250064r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2025.04.011","article-title":"Exploring bimekizumab for psoriasis treatment: multicentre perspectives from Canada.","volume":"21","author":"Lovegrove","year":"2025","journal-title":"JAAD Int"},{"issue":"4","key":"doi250064r21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/bjd\/ljad429","article-title":"Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3?years of treatment in randomized phase III trials.","volume":"190","author":"Gordon","year":"2024","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi250064r22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/ajd.14254","article-title":"Drug survival of biologics in psoriasis: an Australian multicentre retrospective study.","volume":"65","author":"Ting","year":"2024","journal-title":"Australas J Dermatol"},{"issue":"6","key":"doi250064r23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bjd.19701","article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.","volume":"184","author":"Graier","year":"2021","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi250064r24","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/ced.15157","article-title":"Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.","volume":"47","author":"Soenen","year":"2022","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"doi250064r25","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/jvc2.491","article-title":"Ixekizumab trough concentrations in psoriasis: paving the way towards personalised therapy: a cohort study.","volume":"3","author":"Schots","year":"2024","journal-title":"JEADV Clin Pract"},{"issue":"7","key":"doi250064r26","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis.","volume":"57","author":"Bruin","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"doi250064r27","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis.","volume":"138","author":"Reich","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"11","key":"doi250064r28","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.jid.2023.04.009","article-title":"Drug survival of adalimumab, secukinumab, and ustekinumab in psoriasis as determined by either dose escalation or drug discontinuation during the first 3 years of treatment - a nationwide cohort study.","volume":"143","author":"Thein","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi250064r29","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis.","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2843485\/jamadermatology_schwarz_2026_oi_250064_1770869581.734.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:00:18Z","timestamp":1771430418000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2843485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.5205","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}